TY - JOUR
T1 - A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure.
AU - Iwanaga, Yoshitaka
AU - Gu, Yusu
AU - Dieterle, Thomas
AU - Presotto, Cristina
AU - Del Soldato, Piero
AU - Peterson, Kirk L.
AU - Ongini, Ennio
AU - Condorelli, Gianluigi
AU - Ross, John
PY - 2004
Y1 - 2004
N2 - Nitric oxide (NO) production is known to be impaired in heart failure. A new compound (NCX 899), a NO-releasing derivative of enalapril was characterized, and its actions were evaluated in Bio 14.6 cardiomyopathic (CM) hamsters with heart failure. The hamsters were randomized to oral treatment for 4 weeks with vehicle (n=11), NCX 899 (NCX, 25 mg/kg, n=10), or enalapril (25 mg/kg, n=10). In the vehicle group, fractional shortening by echocardiography decreased (-23.6+/-2.0%) and LV end-diastolic dimension) increased (+10.9+/-1.0%), whereas fractional shortening increased (+17.5+/-4.4%) in NCX and was unchanged in the enalapril group (both P
AB - Nitric oxide (NO) production is known to be impaired in heart failure. A new compound (NCX 899), a NO-releasing derivative of enalapril was characterized, and its actions were evaluated in Bio 14.6 cardiomyopathic (CM) hamsters with heart failure. The hamsters were randomized to oral treatment for 4 weeks with vehicle (n=11), NCX 899 (NCX, 25 mg/kg, n=10), or enalapril (25 mg/kg, n=10). In the vehicle group, fractional shortening by echocardiography decreased (-23.6+/-2.0%) and LV end-diastolic dimension) increased (+10.9+/-1.0%), whereas fractional shortening increased (+17.5+/-4.4%) in NCX and was unchanged in the enalapril group (both P
UR - http://www.scopus.com/inward/record.url?scp=2442640601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442640601&partnerID=8YFLogxK
M3 - Article
C2 - 14734637
AN - SCOPUS:2442640601
SN - 0892-6638
VL - 18
SP - 587
EP - 588
JO - FASEB Journal
JF - FASEB Journal
IS - 3
ER -